Non–vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction
Background: Dose reduction of non–vitamin K antagonist oral anticoagulants (NOACs) is
indicated in patients with atrial fibrillation (AF) with renal impairment. Failure to reduce the
dose in patients with severe kidney disease may increase bleeding risk, whereas dose
reductions without a firm indication may decrease the effectiveness of stroke prevention.
Objectives: The goal of this study was to investigate NOAC dosing patterns and associated
outcomes, ie, stroke (ischemic stroke and systemic embolism) and major bleeding in …
indicated in patients with atrial fibrillation (AF) with renal impairment. Failure to reduce the
dose in patients with severe kidney disease may increase bleeding risk, whereas dose
reductions without a firm indication may decrease the effectiveness of stroke prevention.
Objectives: The goal of this study was to investigate NOAC dosing patterns and associated
outcomes, ie, stroke (ischemic stroke and systemic embolism) and major bleeding in …
[HTML][HTML] Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction
AA Khan, GYH Lip - Annals of Translational Medicine, 2017 - ncbi.nlm.nih.gov
Atrial fibrillation (AF) is the commonest cardiac arrhythmia and is an independent risk factor
for stroke and mortality. Oral anticoagulation is the cornerstone of management for primary
and secondary stroke prophylaxis in patients with AF and known additional risk factors (1).
Whilst oral vitamin K antagonists (VKA) such as warfarin were the mainstay of treatment for
decades, they have been superseded by the newer non-vitamin K antagonist oral
anticoagulants (NOACs), which offer relative efficacy, safety and convenience compared to …
for stroke and mortality. Oral anticoagulation is the cornerstone of management for primary
and secondary stroke prophylaxis in patients with AF and known additional risk factors (1).
Whilst oral vitamin K antagonists (VKA) such as warfarin were the mainstay of treatment for
decades, they have been superseded by the newer non-vitamin K antagonist oral
anticoagulants (NOACs), which offer relative efficacy, safety and convenience compared to …
以上显示的是最相近的搜索结果。 查看全部搜索结果